Bristol-Myers Squibb (BMY)
NYSE: BMY · Pharmaceuticals · Princeton, NJ
Our rating: Positive
Positive reaffirmed at $62.48, moderate conviction, October 30, 2026.
Breaks if: The positive view breaks if full-year revenue falls more than 3% in the next annual filing — a move that would signal the growth portfolio is failing to replace lost volume and that flat revenues were a high-water mark rather than a trough. It also breaks if trailing twelve-month free cash flow drops below $10B within the next four quarters, which would collapse the FCF yield anchoring the call. Either condition, confirmed within twelve months of this publication, would shift the view negative.
Key figures
| Market value | $120.2B |
|---|---|
| Revenue, last 12 months | $50.0B |
| Net income, last 12 months | $9.2B |
| Free cash flow, last 12 months | $9.3B |
| Price to earnings | 13.0× |
| Free cash flow yield | 7.7% |
| Dividend yield | 4.3% |
| Operating margin | n/a |
| Return on equity | 44.1% |
| Beta to the S&P 500 | 0.23 |
| Volatility, annualized | 29.0% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $13.1B | 6.9% | $1.05 | $3.8B |
| June 30, 2026 | $13.0B | 5.7% | $1.62 | $3.1B |
| March 31, 2026 | $11.5B | 2.6% | $1.31 | $757M |
| December 31, 2025 | $12.5B | 1.3% | $0.53 | $1.6B |
| September 30, 2025 | $12.2B | 2.8% | $1.08 | $6.0B |
| June 30, 2025 | $12.3B | 0.6% | $0.64 | $3.6B |
| March 31, 2025 | $11.2B | −5.6% | $1.20 | $1.7B |
| December 31, 2024 | $12.3B | 7.5% | $0.04 | $4.1B |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $13.0B: Claude 72%, Gemini 90%, Mistral 78%
- Diluted earnings per share are at least $0.53: Claude 65%, Gemini 95%, Mistral 88%
- Free cash flow for the quarter is at least $1.60B: Claude 60%, Gemini 85%, Mistral 72%
16 ledger entries and 33 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.